CNCR - (Loncar Cancer Immunotherapy ETF)

 CNCRのチャート


 CNCRの企業情報

symbol CNCR
会社名
分野(sector)   
産業(industry)   
業種   
概要 事業概要 --     The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/cncr
adr_tso
EBITDA EBITDA ー
終値(lastsale) 23.16
時価総額(marketcap) 52110000
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 CNCRのテクニカル分析


 CNCRのニュース

   Assessing The Healthcare Selloff  2019-05-04
By Marshall Gordon and Nicholas Wu, PhD Healthcare stocks normally react to political rhetoric, but the speed and magnitude of the recent correction in the sector have been surprising. Despite bipartisan clamoring for broad changes to the healthcare system and the Trump administration'…
   Assessing The Healthcare Selloff  2019-05-04
By Marshall Gordon and Nicholas Wu, PhD Healthcare stocks normally react to political rhetoric, but the speed and magnitude of the recent correction in the sector have been surprising. Despite bipartisan clamoring for broad changes to the healthcare system and the Trump administration'…

 関連キーワード  (― 米国株 CNCR Loncar Cancer Immunotherapy ETF)

 twitter  (公式ツイッターやCEOツイッターなど)